Ligand Pharmaceuticals Incorporated P/E Ratio 2009–2025
Ligand Pharmaceuticals Incorporated reported 30.84 of price-to-earnings ratio for fiscal 2025. That was 27.0% higher than fiscal 2023. Compared with fiscal 2019, the change was +1409.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 30.84 | — |
| FY 2024 | — | — |
| FY 2023 | 24.29 | — |
| FY 2022 | — | — |
| FY 2021 | 29.11 | — |
| FY 2020 | — | — |
| FY 2019 | 2.04 | -85.6% |
| FY 2018 | 14.20 | -91.2% |
| FY 2017 | 161.17 | — |
| FY 2016 | — | — |
| FY 2015 | 6.25 | -89.5% |
| FY 2014 | 59.28 | -0.6% |
| FY 2013 | 59.66 | — |
| FY 2012 | — | — |
| FY 2011 | 15.11 | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Ligand Pharmaceuticals Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open LGND 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Ligand Pharmaceuticals Incorporated reported 30.84 of price-to-earnings ratio for fiscal 2025. That was 27.0% higher than fiscal 2023. Compared with fiscal 2019, the change was +1409.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Ligand Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeLigand Pharmaceuticals Incorporated — frequently asked questions
What is Ligand Pharmaceuticals Incorporated's price-to-earnings ratio?
Ligand Pharmaceuticals Incorporated (LGND) reported price-to-earnings ratio of 30.84 for fiscal year 2025, per its SEC filings.
How has Ligand Pharmaceuticals Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, LGND's price-to-earnings ratio grew at roughly 4.6% per year (compound annual rate), from 15.11 to 30.84.
Where does this data come from?
Figures are computed from Ligand Pharmaceuticals Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More LGND financial history
Full LGND fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →